Zdrowie i gospodarka · 20/05/2025
FDA Establishes Public Docket for Dihydropyrimidine Dehydrogenase Deficiency and Fluoropyrimidine Chemotherapy Drugs
The FDA is soliciting public comment on dihydropyrimidine dehydrogenase deficiency and the use of fluorouracil and capecitabine, fluoropyrimidine chemotherapy drugs, to foster transparency and gather input on available information.
Source: Federal Register — Food and Drug AdministrationOpen original release →